Tradingfxdaily.com
  • Home
  • Forex
  • Crypto News
    • NFT News
  • World News
  • Business
  • Stock Market
  • Economic Calendar
No Result
View All Result
  • Home
  • Forex
  • Crypto News
    • NFT News
  • World News
  • Business
  • Stock Market
  • Economic Calendar
No Result
View All Result
Tradingfxdaily.com
No Result
View All Result
Home World News

Toronto boy whose parents raised $3M to treat his rare genetic disorder starts clinical trial

tradingfxdaily by tradingfxdaily
August 15, 2022
in World News
0
Toronto boy whose parents raised $3M to treat his rare genetic disorder starts clinical trial
189
SHARES
1.5k
VIEWS
Share on FacebookShare on Twitter

Related articles

Sunak migration plan would cost £1bn a year, say campaigners

Sunak migration plan would cost £1bn a year, say campaigners

January 31, 2023
Black woman who fought enslavement honoured with Canada Post stamp – National

Black woman who fought enslavement honoured with Canada Post stamp – National

January 31, 2023

After his parents desperately raised $3 million over four years trying to find a cure for their son’s rare genetic disease, Michael Pirovolakis is one step closer to possible recovery.

Michael, 4, is the only child in Canada diagnosed with Spastic paraplegia 50 (SPG50), a slowly-progressing neurodegenerative disorder that generally presents with global developmental delay resulting in cognitive impairment and eventual paralysis. 

This past March, doctors at the Hospital for Sick Children in Toronto injected a normal version of the gene he’s missing into Michaels’ spinal fluid to be delivered to his brain. The one-dose therapy is part of a groundbreaking clinical trial where Michael is the only participant. 

And already, Georgia and Terry Pirovolakis, Michael’s parents, say they are seeing some signs of hope.

Georgia says goodbye to Michael before his procedure at the Hospital for Sick Children in Toronto in March. (The Hospital for Sick Children)

“You know, we’re cautiously optimistic, let’s call it that, we are seeing some improvements,” said Georgia. “Pointing or playing with his toys, you know, grabbing a truck and actually pushing it, he’s doing all these things that he never did before.”

“It’s our hope that, you know, he becomes normal, obviously a normal boy, you know, lives his life able to communicate, walk, whatever else. But, you know, again, if he’s able to be mobile, be vocal, tell us what he wants, I think that would be a huge win for us.”

The first single, individual clinical trial

When Georgia and Terry were told in 2019 that their 18-month-old son might never walk or talk, they said they were devastated. They were also determined to find a potential cure where none existed.

Through a GoFundMe page and community fundraisers, they raised more than $3 million in donations to finance the development of a specialized gene therapy that could replace the mutated or missing gene causing Michael’s condition. With the help of scientists around the world, a prototype was developed, and once the therapy had been successfully tested in animal models in the lab, it was ready to be given to Michael. 

“In gene therapy, that really is the strategy,” said Dr. Jim Dowling, a staff physician in the division of neurology and senior scientist in the Genetics & Genome Biology program at the Hospital for Sick Children, who led Michael’s clinical trial and was the doctor who first diagnosed him.

“We think it’s one of the first times someone has taken the strategy of gene therapy and done a single individual clinical trial, so we’re very excited for the results for Michael for this trial, but also what it could mean for other children with rare diseases,” he said.

A doctor stands over a child in a hospital room while looking at an image of his spine.
Neuroradiologist Dr. Manohar Shroff during Michael’s procedure at the Hospital for Sick Children. (The Toronto Hospital for Sick Children)

The expectation is the treatment will stop the progression of the disease and perhaps even reverse some degeneration that has already set in, he explained, adding that improvements in Michael’s cognitive and mobility abilities should become apparent in the next several months. The Hospital for Sick Children will monitor his progress for the next five years.

“Obviously the hope is that it will reverse some of the problems that have already been presented and enable him to gain functions he didn’t have before,” said Dowling.

Therapy could help others with rare conditions

And, further to helping Michael, the therapy developed to treat him has the potential to help thousands of other children with rare conditions. Doctors involved in the trial said they hope the lessons learned here could be developed to help in those cases as well.

“As a physician, this gives me hope that the future is brighter, hopefully for him and definitely for many children for many generations,” said Dr. David Malkin, the co-lead for Precision Child Health at the Hospital for Sick Children. “Learnings from Michael’s trial will help carve out a path for SickKids to explore innovative, precision-based treatment options for other patients with rare, genetic diseases.”

Michael’s gene therapy was granted FDA approval on Thursday of last week and his family plans to keep raising money to help fund a clinical trial for other children through a foundation they set up to help Michael. Those trials could start as early as October.

A woman, child, and man smile together.
Georgia, Michael and Terry Pirovolakis are pictured after Michael’s physiotherapy session in Toronto on Aug. 11, 2022. (Ousama Farag/CBC)

That momentum is something the Pirovolakis’ say they hope will inspire other families to keep fighting for their own children, even when the path forward seems dark.

“This is the kind of hope that I think we need to give to people out there and show that, you know, if you work hard enough, raise enough money and you have amazing people to support you, you can do this,” said Terry.

“It’s not easy, you have to work the hardest you’ve ever worked in your life, but you can do this.”

Source link

Share76Tweet47

Related Posts

Sunak migration plan would cost £1bn a year, say campaigners

Sunak migration plan would cost £1bn a year, say campaigners

by tradingfxdaily
January 31, 2023
0

Sign up to the Inside Politics email for your free daily briefing on the biggest stories in UK politicsGet our...

Black woman who fought enslavement honoured with Canada Post stamp – National

Black woman who fought enslavement honoured with Canada Post stamp – National

by tradingfxdaily
January 31, 2023
0

By Staff The Canadian Press Posted January 31, 2023 7:30 am Descrease article font size Increase article font size A...

Report finds that L’Arche co-founder Jean Vanier sexually abused 25 women

Report finds that L’Arche co-founder Jean Vanier sexually abused 25 women

by tradingfxdaily
January 31, 2023
0

A charitable organization founded by the late Jean Vanier issued a report Monday saying the Canadian sexually abused at least...

France, Australia to supply ammo for Ukraine – POLITICO

France, Australia to supply ammo for Ukraine – POLITICO

by tradingfxdaily
January 31, 2023
0

France and Australia will jointly supply Ukraine with 155mm shells, which are notably used by Caesar cannons, their foreign ministries...

Dominic Raab facing calls for third probe over ‘obscene’ language in Commons

Tory MPs call for Dominic Raab to resign as top civil servant gives evidence

by tradingfxdaily
January 31, 2023
0

Sign up to the Inside Politics email for your free daily briefing on the biggest stories in UK politicsGet our...

Load More
  • Trending
  • Comments
  • Latest
Short SPX: Top Trade Opportunities

Short SPX: Top Trade Opportunities

April 5, 2022
The Top 5 Metaverses to Look Out for in 2022

The Top 5 Metaverses to Look Out for in 2022

March 26, 2022
What is Leverage in Forex? Forex Leverage Explained

What is Leverage in Forex? Forex Leverage Explained

April 19, 2022

Larry Fink says globalization is over — Here’s what it means for the markets

March 26, 2022
Tesla Stock Split: What to Know as EV Maker Prepares to Split Its Stock in 2022

Tesla Stock Split: What to Know as EV Maker Prepares to Split Its Stock in 2022

March 28, 2022
How AI can make the metaverse a more interactive space

How AI can make the metaverse a more interactive space

0

In a Less-Globalized World, Be Careful Where You Park Your Plane

0
Cardano pares most of its Q1 losses as ADA rebounds 60% in a month — What’s next? By Cointelegraph

Cardano pares most of its Q1 losses as ADA rebounds 60% in a month — What’s next? By Cointelegraph

0

Larry Fink says globalization is over — Here’s what it means for the markets

0
Natural-Gas Industry Gets Boost as Biden Shifts Stance

Natural-Gas Industry Gets Boost as Biden Shifts Stance

0
How AI can make the metaverse a more interactive space

How AI can make the metaverse a more interactive space

January 31, 2023
Stock Futures Muted as Investors Weigh Fresh Economic Data

Stock Futures Muted as Investors Weigh Fresh Economic Data

January 31, 2023
AUD/USD hits fresh daily high post-NFP, lacks follow-through beyond mid-0.6800s

AUD/USD struggles near one-week low around 0.7000 amid softer risk tone, USD strength

January 31, 2023
Sunak migration plan would cost £1bn a year, say campaigners

Sunak migration plan would cost £1bn a year, say campaigners

January 31, 2023
U.S. securities regulator probes Didi Global’s $4.4 billion IPO By Reuters

India’s Adani rides out storm as investors rally to $2.5 billion share sale By Reuters

January 31, 2023
Tradingfxdaily.com

Tradingfxdaily.com is your Forex, Stock News, World News, Crypto Currency News, Business News & NFT News Website. We provide you with the latest breaking news and videos straight from the Trading industry.

  • Home
  • About us
  • Contact Us
  • Privacy Policy

© 2022 - All Right Reserved. tradingfxdaily.com

No Result
View All Result
  • Home
  • Forex
  • Crypto News
    • NFT News
  • World News
  • Business
  • Stock Market
  • Economic Calendar

© 2022 - All Right Reserved. tradingfxdaily.com

EURUSD=X 
$1.09  -0.02%  
EURCAD=X 
$1.46  0.21%  
EURJPY=X 
$140.96  -0.36%  
GBPUSD=X 
$1.23  -0.26%  
EURNZD=X 
$1.68  0.20%  
AUDUSD=X 
$0.7027  -0.50%  
CADUSD=X 
$0.7457  -0.18%